Predicting gastric cancer response to chemotherapy using AI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a deep-learning model that predicts how well gastric cancer patients will respond to neoadjuvant chemotherapy. By analyzing CT imaging data, biopsy pathology images, and clinical information from participants, the model will forecast treatment efficacy and prognosis. The research will utilize data from 1,800 retrospective cases and 200 prospective cases, with the retrospective data used to train the model and the prospective data to validate its performance. The ultimate goal is to assist in personalized treatment decisions for gastric cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older;
* Pathologically diagnosed with advanced gastric cancer in accordance with the American AJCC's TNM staging standards;
* Have not undergone any systematic anti-cancer treatments before neoadjuvant chemotherapy and have not had surgery for local progression or distant metastasis;
* Received standard neoadjuvant chemotherapy as recommended by the clinical guidelines, and have documented treatment details;
* CT imaging and biopsy pathology images strictly taken within one month prior to starting neoadjuvant treatment;
* Patients possess comprehensive preoperative clinical information and post-operative TRG grading.

Exclusion Criteria:

* Patients whose CT or pathology images are unclear, making lesion assessment infeasible;
* Patients diagnosed with other concurrent tumors.

Where it's running

• Peking University Cancer Hospital & Institute
  Beijing, China Recruiting
• Fujian Medical University Union Hospital
  Fuzhou, China Recruiting
• Sixth Affiliated Hospital, Sun Yat-sen University
  Guangzhou, China Recruiting
• Yunnan Cancer Hospital
  Kunming, China Recruiting
• Henan Cancer Hospital
  Zhengzhou, China Recruiting
• The First Affiliated Hospital of Zhengzhou University
  Zhengzhou, China Recruiting

Study contacts

• Study coordinator: Di Dong, Ph.D.
• Email: di.dong@ia.ac.cn
• Phone: +86 13811833760

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.